Subconjunctival bevacizumab for corneal neovascularization

被引：65

作者：

Doctor, Priyanka P. ^{[1
]}

Bhat, Pooja V. ^{[1
]}

Foster, C. Stephen ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Eye Res & Surg Inst, Ocular Immunol & Uveitis Fdn, Cambridge, MA 02142 USA

来源：

CORNEA | 2008年 / 27卷 / 09期

关键词：

subconjunctival bevacizumab; avastin; corneal neovascularization;

D O I：

10.1097/ICO.0b013e31817786ad

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To describe whether subconjunctival bevacizumab decreases corneal in patients with ocular surface inflammatory diseases. Methods: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. changes, were assessed clinically by the same investigator at each visit. Results: Subconjunctival bevacizumab was well-tolerated without obvious, corneal side effects. All 8 eyes of the 7 patients showed a recduction in the neovascularized area. Conclusions: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.

引用

收藏

页码：992 / 995

页数：4

相关论文

共 24 条

[1]

Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18

[2] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].

Avery, RL ;

Pieramici, DJ ;

Rabena, MD ;

Castellarin, AA ;

Nasir, MA ;

Giust, MJ .

OPHTHALMOLOGY, 2006, 113 (03) :363-372

[3] Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy [J].

Avery, Robert L. ;

Pearlman, Joel ;

Pieramici, Dante J. ;

Rabena, Melvin D. ;

Castellarin, Alessandro A. ;

Nasir, Ma'an A. ;

Giust, Matthew J. ;

Wendel, Robert ;

Patel, Arun .

OPHTHALMOLOGY, 2006, 113 (10) :1695-1705

[4] Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration [J].

Bashshur, Ziad F. ;

Bazarbachi, Ali ;

Schakal, Alexandre ;

Haddad, Zeina A. ;

El Haibi, Christelle P. ;

Noureddin, Baha' N. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :1-9

[5] The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization [J].

Benelli, U ;

Bocci, G ;

Danesi, R ;

Lepri, A ;

Bernardini, N ;

Bianchi, F ;

Lupetti, M ;

Dolfi, A ;

Campagni, A ;

Agen, C ;

Nardi, M ;

Del Tacca, M .

EXPERIMENTAL EYE RESEARCH, 1998, 67 (02) :133-142

[6] Corneal neovascularization [J].

Chang, Jin-Hong ;

Gabison, Eric E. ;

Kato, Takuji ;

Azar, Dimitri T. .

CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (04) :242-249

[7] A NEW CLASS OF STEROIDS INHIBITS ANGIOGENESIS IN THE PRESENCE OF HEPARIN OR A HEPARIN FRAGMENT [J].

CRUM, R ;

SZABO, S ;

FOLKMAN, J .

SCIENCE, 1985, 230 (4732) :1375-1378

[8] Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization [J].

Cursiefen, C ;

Rummelt, C ;

Küchle, M .

CORNEA, 2000, 19 (04) :526-533

[9] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[10] Topical bevacizumab therapy for corneal neovascularization [J].

DeStafeno, John J. ;

Kim, Terry .

ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (06) :834-836